Hims & Hers Health, Inc. reported an insider sale from its chief operating officer on March 17, 2026. Michael Chi sold 97,289 shares of Class A Common Stock at $24.69 per share in a transaction that totaled approximately $2.4 million. After the disposition, Chi retains direct ownership of 407,282 shares of the company.
The sale was carried out pursuant to a Rule 10b5-1 trading arrangement that Chi put in place on March 4, 2025. The 10b5-1 framework permits scheduled trading by insiders and is commonly used to insulate transactions from questions about contemporaneous information.
Chi's share sale arrives amid a period of notable activity for Hims & Hers. The company announced a collaboration with Novo Nordisk that allows it to offer doses of both Ozempic and Wegovy as part of its weight loss care lineup, including distribution of a newly introduced pill form. As a result of the agreement, Novo Nordisk dropped its lawsuit against Hims & Hers. Those developments were followed by at least one analyst upgrade, with BofA Securities revising its rating from Underperform to Neutral and increasing its price target to $23.00.
Leadership changes have also been disclosed. Kathryn Beiser has been named chief communications officer and will be responsible for external and internal communications as the company pursues its expansion initiatives.
Market reaction to the string of corporate updates has been pronounced. The stock recorded a 64% rally through Wednesday, marking what the company characterized as its best week on record. Trading momentum included a 10% increase on Tuesday, with subsequent sessions producing additional gains.
Collectively, the insider sale and the company's recent partnership, legal resolution, analyst attention, executive appointment, and sharp share-price appreciation reflect a concentrated episode of corporate and market activity for Hims & Hers. The 10b5-1 plan under which Chi's sale was executed indicates the transaction followed a pre-established schedule rather than an ad hoc decision tied to the recent public developments.
The facts reported here are limited to the company filings and public announcements cited in the transaction notice and related disclosures. Where the underlying materials provide limited detail, this report reflects those limits rather than extending beyond the information supplied.